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Xenotropic murine leukemia virus-related virus (XMRV) is a virus created through recombination of 
two murine leukemia proviruses under artificial conditions during the passage of human prostate 
cancer cells in athymic nude mice. The homodimeric protease (PR) of XMRV plays a critical role in 
the production of functional viral proteins and is a prerequisite for viral replication. We synthesized 
XMRV PR using the wheat germ cell-free expression system and carried out structural analysis of 
XMRV PR in a complex with an inhibitor, amprenavir (APV), by means of NMR. Five different 
combinatorially 15N-labeled samples were prepared and backbone resonance assignments were made 
by applying Otting's method, with which the amino acid types of the [1H, 15N] HSQC resonances were 
automatically identified using the five samples (Wu et al., 2006). A titration experiment involving 
APV revealed that one APV molecule binds to one XMRV PR dimer. For many residues, two distinct 
resonances were observed, which is thought to be due to the structural heterogeneity between the two 
protomers in the APV:XMRV PR = 1:2 complex. PR residues at the interface with APV have been 
identified on the basis of chemical shift perturbation and identification of the intermolecular NOEs by 
means of filtered NOE experiments. Interestingly, chemical shift heterogeneity between the two 
protomers of XMRV PR has been observed not only at the interface with APV but also in regions apart 
from the interface. This indicates that the structural heterogeneity induced by the asymmetry of the 
binding of APV to the XMRV PR dimer is transmitted to distant regions. This is in contrast to the case 
of the APV:HIV-1 PR complex, in which the structural heterogeneity is only localized at the interface. 
Long-range transmission of the structural change identified for the XMRV PR complex might be 




Xenotropic murine leukemia virus-related virus (XMRV) has been implicated in prostate cancer [1] 
and chronic fatigue syndrome [2]. These reports have attracted much attention since a causal 
relationship between a retrovirus and a human disease had only been known for HIV and AIDS [3]. 
After several years of controversial research, a recent study has indicated that XMRV was generated 
through the recombination of two proviruses during the passaging of human tumors in mice [4]. Thus, 
XMRV is as not yet regarded as an etiological agent for human diseases, however, it can be considered 
as a rational example of a gammaretrovirus that can infect human cells and replicate within them. 
Proteases (PRs) of viruses such as those of the HIV-1 and hepatitis C ones have been prime 
targets for antiviral drug development. Although hundreds of inhibitors have been discovered for 
HIV-1 PR for example, only a few of them are potent antiprotease drugs that are in clinical use [5]. 
Additionally, long-term administration of these drugs causes the emergence of drug-resistant mutants 
[6]. It is expected that a detailed description of the interaction between a newly found protease of the 
retrovirus family and its cognate substrate or inhibitor may provide valuable information. 
XMRV PR is a homodimer, each subunit (protomer) comprising 125 amino acids with a single 
catalytic Asp residue [7,8]. XMRV PR processes viral polyproteins to yield mature proteins required in 
the viral life cycle, as is the case for HIV-1 PR. The sequence identity between and similarity of these 
two proteins are 21% and 27%, respectively, over 99 amino acid residues with a single gap (sequences 
aligned with ClustalW2 [9,10]). The crystal structures of XMRV PR have been solved in both the free 
form and complex forms with several inhibitors [7,8]. The fold of XMRV PR is similar to that of 
HIV-1 PR. The overall structural similarity between the protomer of XMRV PR (PDB ID: 3NR6; [7]) 
and that of HIV-1 PR (99 amino acids; PDB ID: 3HVP; [11]) in the free form was found to be 1.04 Å 
of RMSD over 53 C atoms (calculated using CHIMERA [12]). 
In the present study, we used our established wheat germ protein production system to obtain 
otherwise cell-toxic XMRV PR [13]. This system allowed us to obtain not only a large amount of free 
and amprenavir (APV)-bound XMRV PR, but also uniformly and combinatorially isotope-labeled 
samples. The latter isotope-labeled samples made it possible to apply Otting's rapid assignment 
strategy [14] in combination with conventional protocols [15]. It was critical to utilize this strategy for 
accomplishment of the assignments. We found that the asymmetry of the binding for the APV:XMRV 
PR=1:2 complex results in the structural heterogeneity between the two protomers of XMRV PR at the 
interface, and, but more importantly, in regions distant from the interface. In the case of the binding of 
APV to HIV-1 PR, in contrast, the asymmetry causes structural heterogeneity only at the interface. 
 
2. Materials and methods 
2.1 Sample preparation 
XMRV PR comprising 1-125 residues with an additional threonine residue at the C-terminal end, was 
synthesized by means of our wheat germ cell-free expression system as an N-terminal 
glutathione-S-transferase (GST) fusion protein. The XMRV PR fragment was cloned by PCR from the 
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XMRV VP62 clone [16,17] (UniProt ID: A1Z651) and subcloned into pEU-E01-GW [18] with the DNA 
sequences of the GST gene and Tobacco Etch Virus Protease (TEV) cleavage site. This plasmid DNA was 
subjected to in vitro transcription and cell-free protein synthesis with the wheat germ protein production 
system [13]. Cell-free protein production was carried out using the ENDEXT.AN. Wheat Germ Expression 
Kit and according to the instructions provided by the supplier (CellFree Sciences Co., Ltd., Matsuyama, 
Japan). The cell-free protein production and cleavage purification were also carried out using an automatic 
robot, Protemist DTII (CellFree Sciences Co., Ltd.), basically according to manufacturer's instructions. 
GST-XMRV PR was synthesized either in the absence or presence of APV. After the synthesis, the 
protein solution was loaded onto a Glutathione-Sepharose 4B column (GE Healthcare), and the bound 
GST-XMRV PR was washed thoroughly with PBS buffer. Subsequently, GST-fused TEV protease 
(Nacalai Tesque) was applied to cleave the XMRV PR off on-column. The XMRV PR was then 
collected and dialyzed against either 20 mM sodium phosphate (pH 6.5), 50 mM NaCl and 10 M 
APV for the APV-bound XMRV PR or 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl for APV-free 
XMRV PR. As substrates for protein synthesis, isotropically labeled amino acids were used to synthesize 
uniformly 15N- and 15N, 13C-labeled ([U-15N] and [U-13C, U-15N], respectively) XMRV PRs. Five 
different combinatorially 15N-labeled samples of XMRV PR were prepared following Otting's labeling 
scheme, as shown in Fig. 1C [14]. 
 
2.2 NMR spectroscopy 
For XMRV PR in a complex with APV, NMR spectra were acquired at 22.9°C using Bruker 600 and 
950 MHz spectrometers each equipped with a cryoprobe. Data were processed and analyzed using 
NMRPipe [19] and Kujira [20]. The sample solutions comprised 0.1 - 0.3 mM protein in a complex 
with APV, 20 mM sodium phosphate (pH 6.5), 50 mM NaCl, 10 M APV, and 5% D2O. The amino 
acid in [1H, 15N] HSQC spectra were identified using the five different combinatorially 15N-labeled 
samples according to Wu et al. [14]. Sequential assignments of the main chain resonances were made 
by means of conventional triple resonance experiments [15,21,22]. The main chain 1HN and 15N 
chemical shift heterogeneity between the two protomers in the APV:XMRV PR=1:2 complex was 
defined as {(Δδ1HN)2 +(Δδ15N/5)2 }1/2, where Δδ1HN and Δδ15N are the chemical shift differences 
between the two protomers for 1HN and 15N resonances, respectively. The secondary structures of 
XMRV PR in a complex with APV was identified based on 13Cα, 13Cβ and 13C' chemical shift values 
[23]. The intermolecular NOEs between XMRV PR and APV were obtained from 2D [F1, F2] 13C, 
15N-filtered NOESY (120 ms mixing time), 2D [F2] 13C, 15N-filtered NOESY (120 ms mixing time), 
3D [F1] 13C, 15N-filtered, [F2] 13C-edited NOESY (120 ms mixing time) [24], and 3D 13C-edited 
NOESY (78 ms mixing time) spectra. 
For free XMRV PR, NMR spectra were acquired at 15.0°C using a Bruker 600 MHz spectrometer 
equipped with a cryoprobe. The sample solutions comprised ~ 0.1 mM protein, 20 mM Tris-HCl (pH 
8.0), 50 mM NaCl and 5% D2O. Partial assignments of the main chain 
1HN and 15N resonances were 
made using 3D 15N-edited NOESY spectra utilizing on the assignments for the XMRV PR-APV 
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complex as a reference. The main chain 1HN and 15N chemical shift perturbations between the free and 
APV-bound forms of XMRV PR were defined as {(Δδ1HN)2 +(Δδ15N/5)2 }1/2, where Δδ1HN and Δδ15N 
are the chemical shift differences between the free and APV-bound forms for 1HN and 15N resonances, 
respectively. For the APV-bound form, the average of the chemical shift values for the two protomers 
was used to calculate the differences. 
 
3. Results and Discussion 
3.1. Characteristics of the [1H, 15N] HSQC spectrum of the XMRV PR in complex with APV 
We have successfully obtained cell-toxic XMRV PR by using a cell-free protein synthesis system in 
both the presence and absence of APV. Moreover, we were able to prepare [U-15N] and [U-13C, U-15N] 
labeled, and five different combinatorially 15N-labeled samples of XMRV PR, all of which critically 
facilitated our NMR analyses. 
    First, titration with APV was carried out. Disappearance of the resonances of XMRV PR in the 
free state and simultaneous appearance of new resonances for the APV-bound form were observed in 
the [1H, 15N] HSQC spectrum during the titration. This indicates that the free and bound forms of 
XMRV PR are in a slow exchange regime on an NMR time scale. Such spectral changes for XMRV 
PR were seen until APV:XMRV PR=1:2, but no further change was seen on further addition of APV. 
This indicates that the stoichiometry is one APV molecule per one XMRV PR dimer (two XMRV PR 
monomers). 
Each protomer comprises 126 amino acid residues, including 12 proline ones. If the homodimer 
exhibits symmetry, maximally 113 backbone resonances are expected to be observed, because those of 
the N-terminus and proline residues do not appear. However, the [1H, 15N] HSQC spectrum contained 
more than 1.5-times as many backbone resonances as expected (Fig. 1A). This observation reveals that 
the APV-bound XMRV PR exhibits asymmetry. 
 
3.2 Sequence-specific resonance assignments and identification of the secondary structure of the 
XMRV PR in a complex with APV 
We applied Otting’s strategy, with which amino acids could be automatically identified on the basis of 
the comparison of five spectra [14]. Assignments of the 1HN, 15N, 13C, 13C, and 13C' backbone 
resonances of XMRV PR in complex with APV were carried out with the knowledge of the amino acid. 
Almost all of the observed resonances were successfully assigned. It was found that two distinct 
backbone resonances were observed for many residues of XMRV PR in a complex with APV, which 
resulted in more than 1.5 times as many backbone resonances as expected. The observation of two 
distinct peaks for many residues must be due to that the two protomers of the XMRV PR dimer are not 
identical to each other in the APV:XMRV PR = 1:2 complex. 
The secondary structure of the XMRV PR in a complex with APV was identified according to the 
13Cα, 13Cβ and 13C' chemical shift values [23] (Fig. 1D). It was noticed that the two protomers exhibited 
almost identical secondary structures. The solution structure of XMRV PR in a complex with APV 
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turned out to be basically the same as the crystal structure, which was solved recently [8], as shown in 
Fig. 1D. 
 
3.3 Binding mode of APV as to XMRM PR in solution  
The quality of the [1H, 15N] HSQC spectrum of APV-free XMRV PR appeared to be rather poor due to 
line broadening of resonances in comparison with in the case of APV-bound XMRV PR. By 
comparing the spectral patterns of the 3D 15N-edited NOESY spectra between the APV-bound and 
APV-free forms of XMRV PR, we achieved partial assignment of the main chain 1HN and 15N 
resonances of APV-free XMRV PR. It was found on this analysis that only one set of resonances was 
observed for APV-free XMRV PR. This indicates that the two protomers are symmetric as to each 
other in the APV-free form. We then calculated the chemical shift perturbations of the backbone 
resonances of XMRV PR upon APV binding, and mapped them onto the crystal structure (Fig. 2A). 
The largest perturbations were observed for the residues located close to APV in the crystal structure 
(Fig. 2A). This strongly suggests that in solution APV resides at a similar position to as observed in 
the crystal. 
In order to further confirm the interface of XMRV PR with APV, identification of intermolecular 
NOEs was attempted. First, the 1HN resonances of APV bound to XMRV PR were assigned using the 
2D [F1, F2] 13C, 15N-filtered NOESY spectrum (Fig. 2B). Secondly, the intermolecular NOEs between 
XMRV PR and APV were discriminated by comparing the 2D [F1, F2] 13C, 15N-filtered NOESY and 
2D [F2] 13C, 15N-filtered NOESY spectra (Fig. 2B). That is, NOEs observed in the latter spectrum but 
not in the former one were judged to be intermolecular NOEs. Finally, these intermolecular NOEs 
were assigned by combinational use of the 3D [F1] 13C, 15N-filtered, [F2] 13C-edited NOESY, 3D 
13C-edited NOESY, and 3D 15N-edited NOESY spectra. Consequently, we were able to identify and 
assign the intermolecular NOEs between APV (P1, P1’, P2 and P2’), and either the methyl groups of 
A35, V39, V54, A57, L83 and L92 or the aromatic ring of Y90 (Fig. 2B). These intermolecular NOEs 
turned out to be fully consistent with the crystal structure of the APV:XMRV PR complex. All of the 
listed amino acid residues are indeed located close to APV in the crystal structure (Fig. 2C). This 
revealed that in solution APV binds to XMRV in the same manner as observed in the crystal. 
 
3.4 Long-range transmission of the structural heterogeneity between two protomers in the APV:XMRV 
PR complex 
The 1HN, 15N chemical shift heterogeneity of the backbone resonances between the two protomers of 
XMRV PR in a complex with APV was calculated and mapped onto the crystal structure of the XMRV 
PR:APV complex (Fig. 3A). It turned out that chemical shift heterogeneity was observed not only at 
the APV-binding site (D32, A35, Q36 and L92), but also at positions distant from the APV-binding site 
(S38, L73, H80, S81, L97 and L122). This suggests that the structural heterogeneity occurs not only at 
the interface with APV but also in these regions in the APV:XMRV PR = 1:2 complex. 
Then, we examined the structural heterogeneity of the crystal structure of the APV:XMRV PR 
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complex. The backbone atoms of the two protomers were superimposed and the differences in position 
between the C atoms of the two protomers were calculated to estimate the structural heterogeneity in 
the crystal. The C- C distance was mapped on the crystal structure of the APV:XMRV PR complex 
(Fig. 3B). It is found that structural heterogeneity is present not only at the interface with APV but also 
in regions distant in the crystal structure too. Thus, it was found that the structural heterogeneity 
exhibits long-range transmission in the APV:XMRV PR=1:2 complex in both solution and crystal 
states. 
 
3.5 Long-range transmission of the structural heterogeneity is specific to the APV:XMRV PR complex, 
not being observed in the APV:HIV-1 PR complex 
Next, we examined if the long-range transmission of the structural heterogeneity occurs for PR of 
another virus, HIV-1. The 1HN, 15N chemical shift heterogeneity between the two protomers of HIV-1 
(D25N) PR in a complex with a peptide substrate was calculated using the previously reported data 
[25]. Here, heterogeneity in solution was analyzed for the peptide-bound form, because NMR data on 
HIV-1 in a complex with APV are not available. It has been confirmed that the mutant (D25N) and 
wild-type HIV-1 PRs exhibited essentially identical backbone chemical shift values, except for those 
of mutated residue 25 and adjacent residues [25]. Since the peptide substrate is larger than APV in size 
and has a highly asymmetric structure, this system could be used instead to compare the heterogeneity 
between the XMRV and HIV-1 PRs. The chemical shift heterogeneity values were mapped onto the 
crystal structure of the HIV-1 PR (D25N) in a complex with APV (Fig. 3C). The chemical shift 
heterogeneity was mostly observed for residues located close the substrate/inhibitor–binding site. This 
indicates that the structural heterogeneity is localized around the substrate binding site and that the 
structural heterogeneity is not transmitted to distant regions in the HIV-1 PR, which is in contrast to 
the case of the XMRV PR. 
In order to further confirm the localization of the structural heterogeneity for HIV-1 PR, the 
crystal structure of the APV:HIV-1 PR (D25N) complex was examined. The differences in the 
positions of the C atoms of the two protomers were calculated and mapped onto the crystal structure 
(Fig. 3D). The structural heterogeneity was mostly observed for the residues that are close to the 
substrate-binding site. This is consistent with the conclusion derived from NMR data in solution for 
HIV-1 PR. Thus, the long-range transmission of the structural heterogeneity does not occur in HIV-1 
PR, but is specific to XMRV-PR. 
 
3.6 Implications for discovery of new types of drug on the basis of the identification of long-range 
transmission of the structural heterogeneity 
It has been pointed out for HIV-1 PR that opening and closing of the flap of the binding site 
results in compression and expansion of the shallow groove indicated by the arrow in Fig. 3D, 
respectively [26,27]. Recently, the peripheral surface of HIV-1 PR, which is relatively apart from the 
binding site, was suggested to be a good target for the discovery of allosteric inhibitors. A 
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fragment-based screen against HIV-1 PR in a complex with TL-3, a universal inhibitor of retroviral 
PRs, has been employed using the Active Sight fragment library and X-ray crystallography [28]. The 
authors of that study discovered that 2-methylcyclohexanol binds to the 'exo site' just by the shallow 
groove [28]. This compound binds to the shallow groove and restricts its compression, and thus 
prevents the flap from opening. Therefore, it was proposed that the compound can be used as a starting 
molecule for the development of high-affinity allosteric inhibitors [28]. This example illustrates that a 
drug that binds to a position distant from the binding site can affect the binding affinity, being a 
candidate inhibitor. We have shown that the structural heterogeneity is transmitted away in XMRV PR. 
This means that the heterogeneous structural changes on binding of APV are transmitted to distant 
regions. This implies conversely that a drug that binds to a distant site may affect the structure of the 
substrate-binding site and thus inhibit binding of a substrate. This new type of a drug might be 
discovered more easily for XMRV PR than for HIV-1 PR. Then, in some cases, the discovered drug 
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Figure 1. (A) [1H, 15N] HSQC spectrum of uniformly 13C, 15N-labeld XMRV PR in a complex with 
APV. (B) Superposition of the [1H, 15N] HSQC spectra of five different combinatorially 15N-labeled 
XMRV PRs (1-5 of (C)) in a complex with APV, colored red, cyan, green, magenta and blue, 
respectively. (C) Five different combinatorial labeling schemes [14]. (D) Comparison of the secondary 
structures of XMRV PR in a complex with APV between the crystal [8] and solution (this work) states.  
 
Figure 2. (A) Mapping of the 1HN, 15N chemical shift perturbations between the APV-free and 
APV-bound forms of XMRV PR on to the crystal structure of the APV:XMRV PR complex (PDB 
accession number 3SM2). The N- and C-termini of the two protomers are denoted by N and C, and N’ 
and C’, respectively. (B) 2D [F2] 13C, 15N-filtered NOESY (120 ms mixing time) (blue) and 2D [F1, 
F2] 13C, 15N-filtered NOESY (120 ms mixing time) (red) of XMRV PR in a complex with APV. The 
assigned intermolecular NOE peaks for XMRV PR and APV are labeled. (C) APV bound to XMRV 
PR in the crystal (PDB accession number 3SM2). The protomers of XMRV PR are shown in yellow 
and gray, respectively. APV, is colored magenta. (D) Chemical structure of APV. 
 
Figure 3. (A) Mapping of the 1HN, 15N chemical shift heterogeneity between the two protomers of 
XMRV PR in a complex with APV on to the crystal structure of the XMRV PR-APV complex (PDB 
accession number 3SM2). (B) Mapping of the C to C distance between the two superimposed 
protomers of the XMRV PR-APV crystal structure. The shallow groove is indicated by an arrow. (C) 
Mapping of the 1HN, 15N chemical shift heterogeneity between the two protomers of the HIV PR 
(D25N) in a complex with a peptide substrate [25] on to the crystal structure of the HIV PR 
(D25N)-APV complex. The structure of APV has been deleted. (D) Mapping of the C to C distance 
between the two superimposed protomers in the HIV PR (D25N)-APV crystal structure. The shallow 
groove is indicated by an arrow. The flap is also indicated. 



